Marilena Vrana Joins ARMONIA 2025 in Athens to Discuss Plasma Access
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”Why does the dependency of Europe on the US for plasma for fractionation persist? What does it mean for patient access and health-systems resilience?
These are some of the questions we will explore at ARMONIA’s 1st Conference on Primary Immunodeficiencies on 12 November in Athens, where I will represent PPTA Europe, Plasma Protein Therapeutics Association (PPTA).
Plasma and plasma-derived therapies availability is a public-health issue with very real consequences for people whose lives depend on them. I look forward to a forward-looking, evidence-based discussion with all stakeholders present.
CU in Athens.
12 November 2025
Wyndham Grand Athens
Agenda here.”
Keep up with Hemostasis Today.
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch
-
Feb 23, 2026, 16:36Stéphanie Roullet։ New Method to Explore Primary Haemostasis in Cirrhotic Patients
-
Feb 23, 2026, 16:33Salvatore Massimo Petrina: Top 5 Game-Changers in the AHA and ACC PE Guidelines
-
Feb 23, 2026, 16:21Azin Alizadehasl: Introducing the Second Edition of a New Book on Echocardiography and Cardiac MRI
-
Feb 23, 2026, 16:16Kalyan Roy: When and Why Blood Irradiation Matters in Transfusion Medicine
-
Feb 23, 2026, 15:59Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update
-
Feb 23, 2026, 15:54Alan Nurden: From Early Discoveries to New Therapeutic Advances in von Willebrand Disease